it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...

Regular follow-ups can also help doctors monitor signs of hypoglycemia, renal disease, pancreatitis and thyroid cancer. GLP-1 agonists are medications that primarily treat type 2 diabetes and obesity.

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...

The addition of glucagon-like peptide-1 receptor agonists to progestin therapy may help reduce endometrial cancer risk among certain women, according to study results. Findings presented at ...

GLP-1 medications like Ozempic have shown promise as treatment for symptoms caused by Polycystic Ovary Syndrome (PCOS). I ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning stands. So if you do have a family or personal history of MTC ...

There’s also been concern that GLP-1 drugs might increase the risk of a rare form of thyroid cancer in patients taking immune-suppressing drugs to prevent transplant rejection, researchers added.

US -based pharmaceutical giant Eli Lilly recently launched its weight loss drug Mounjaro in India. Tirzepatide is the generic ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only ...